HTTP/1.1 200 OK Server: Apache/2.2.3 (CentOS) X-Powered-By: PHP/5.2.17 Expires: Sun, 19 Nov 1978 05:00:00 GMT Last-Modified: Thu, 07 Mar 2013 09:33:15 GMT Cache-Control: store, no-cache, must-revalidate Cache-Control: post-check=0, pre-check=0 Vary: Accept-Encoding Content-Type: text/html; charset=utf-8 Content-Length: 37424 Date: Thu, 07 Mar 2013 09:33:16 GMT X-Varnish: 1334086858 Age: 0 Via: 1.1 varnish Connection: keep-aliveChina's Proteomics Boom Continues, Though Not Immune from Global Life Sciences Slowdown | GenomeWeb
China's Proteomics Boom Continues, Though Not Immune from Global Life Sciences Slowdown
March 06, 2013
Existing premium subscriberslogin here
New to GenomeWeb?Register here
An international team led by investigators at the Michigan State University and the University of Kentucky havesequenced and assembled the genome of sea lamprey
, Petromyzon marinus, using the sequence to begin refining their understanding of vertebrate evolution. Their work was published online this week inNature Genetics
. The team's analyses of the 816 million base genome assembly uncovered 26,046 predicted protein-coding genes.
Promega issuing Life Technologies
in federal court saying the Carlsbad, Calif.-based company infringes patents held by Promega covering the analysis of small tandem repeat loci for genetic analysis. In its complaint filed in US District Court Western District of Wisconsin, Promega alleges Life Tech and its Applied Biosystems business infringe US Patent No. RE37984 through the sale of AuthentiFiler products. In December, Life Tech sued Promega over the same patent.
After more than a year of on-and-off again negotiations, members of Congress and the White House have failed to reach a compromise agreement toavert the budget sequester penalty
, which will slash $85 billion out of federal discretionary spending this fiscal year. Sequestration was set to take effect on Friday. The National Institutes of Health, the National Science Foundation, the Food and Drug Administration, and all other federal agencies must begin enacting 5 percent budget cuts.
Thelegend of the swan song
has taken hold as a metaphor for a last act before the end. Though this issue ofGenome Technology
is its swan song, it goes out facing the future, with profiles of two dozen up-and-coming investigators intent on making their mark on the life sciences community in fields as varied as clinical cancer sequencing and gene splicing and public health genomics. Their best days are likely ahead, even asGT
's days end.